Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering
Xenetic Biosciences reported a 67.2% increase in Q3 2025 revenue to $1.0 million, driven by increased royalty revenue from a sublicense agreement with Takeda Pharmaceuticals. The company ended the quarter with $4.1 million in cash and completed a $3.9 million public offering. Xenetic continues to advance its DNase I program and collaborate with institutional partners. This summary is based on AI-generated content by Public Technologies.
Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter’s end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
